Antitumor activity studies of newly synthesized N-salicyloyl-N'-(p-hydroxybenzthioyl)hydrazine and its copper(II) complex both in vivo and in vitro.
A new ligand N-salicyloyl-N'-(p-hydroxybenzthioyl) hydrazine (H2STPH) and its Cu(II) complex [Cu(SPTH)] were prepared and characterized by analytical and physicochemical studies. In vivo antitumor activity of [Cu(STPH)] has been tested against breast tumor in C3H/J strain mice and in vitro on P-815 (murine mastocytoma) and K-562 (human erythroleukemia) cells. LD50 values were estimated at a dose level of 100 mg/kg body weight and a light microscopic study also carried out.
Singh
N K
NK
Department of Chemistry, Banaras Hindu University, Varanasi, India.
Singh
N
N
Prasad
G C
GC
Sodhi
A
A
Shrivastava
A
A
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D003300:Copper / Q000737:chemistry*; D004578:Electron Spin Resonance Spectroscopy; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000737:chemistry*; D004915:Leukemia, Erythroblastic, Acute / Q000473:pathology; D009682:Magnetic Resonance Spectroscopy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D012515:Mast-Cell Sarcoma / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D009942:Organometallic Compounds / Q000737:chemistry*; D012457:Salicylamides / Q000737:chemistry*; D013055:Spectrophotometry, Infrared; D014407:Tumor Cells, Cultured
C105908:(N-salicyloyl-N'-(4-hydroxybenzthioyl)hydrazine)copper(II); D000970:Antineoplastic Agents; D006834:Hydrazines; C105907:N-salicyloyl-N'-(4-hydroxybenzthioyl)hydrazine; D009942:Organometallic Compounds; D012457:Salicylamides; D003300:Copper